PMID: 9633903Jun 20, 1998Paper

Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions

British Journal of Haematology
D A MavroudisA J Barrett

Abstract

Accumulating evidence indicates that alloreactive donor T cells confer both graft-versus-host (GVH) and graft-versus-leukaemia (GVL) reactivity following allogeneic bone marrow transplantation. We have developed a method to deplete alloreactive donor T cells with an immunotoxin targeting the alpha chain of the IL-2 receptor. In patients with chronic myeloid leukaemia and their HLA-identical sibling donors, we measured donor helper T-lymphocyte precursor frequencies (HTLPf) against recipient peripheral blood mononuclear cells (PBMNC; donor versus host), recipient leukaemia cells (donor versus leukaemia) and third-party PBMNC, before and after the depletion. In seven pairs there was a 4.3-fold reduction of donor-versus-host HTLPf (P=0.017), without a significant change in the donor frequencies against third party (P=0.96). In eight further donor-recipient pairs, immunotoxin-depleted donor versus patient PBMNC HTLPf 4.5-fold (mean 1/155,000 before and 1/839,000 after depletion, P=0.007). There was a smaller non-significant 1.8-fold reduction in donor-versus-leukaemia HTLPf from 1/192,000 to 1/334,000 (P=0.19). These results suggest that selective T-cell depletion can significantly deplete donor anti-host reactivity while conservin...Continue Reading

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J SoifferR Gonin
Jan 6, 1990·Lancet·V S GharpureS T Durrant
Jan 1, 1997·Stem Cells·A J Barrett

❮ Previous
Next ❯

Citations

Jan 19, 2002·Seminars in Hematology·Benedikt GahnHelen E Heslop
Nov 5, 1999·Current Opinion in Hematology·F Dazzi, J Goldman
Oct 18, 2001·Current Opinion in Hematology·K S Peggs, S Mackinnon
May 10, 2006·Immunology and Cell Biology·Siok-Keen TeyHelen E Heslop
Jan 4, 2013·PloS One·William K DeckerWilliam G Wierda
Sep 13, 2014·Hematology/oncology Clinics of North America·William Bensinger
Dec 5, 2003·Transfusion Medicine·J K Davies, M W Lowdell
Apr 2, 2002·Best Practice & Research. Clinical Haematology·K S Peggs, S Mackinnon
Sep 24, 2002·Hematology·Karl S Peggs, Stephen Mackinnon
Oct 27, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul SzabolcsJoanne Kurzberg
Mar 1, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Congxiao LiuNelson J Chao
Jan 10, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Shai YarkoniNadir Askenasy
Apr 13, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jeffrey K DaviesMark W Lowdell
Feb 16, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Takero ShindoTakashi Uchiyama
Jun 21, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Zachariah A McIverA John Barrett
Jun 21, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephan MielkeA John Barrett
Nov 25, 2000·British Journal of Haematology·J Barrett, R Childs
Aug 3, 2002·Leukemia & Lymphoma·A B T FassasG Tricot
Jul 4, 2001·Bone Marrow Transplantation·R ChamplinS Giralt
Jul 16, 2011·Applied Microbiology and Biotechnology·Stefanie Kind, Christoph Wittmann
Nov 25, 2003·Hematology·A John BarrettNelson Chao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.